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KESAN PENGAMBILAN EKSTRAK CHANNA STRIATUS KE ATAS 
PENANDA-PENANDA PENYEMBUHAN LUKA (IL-6, MMP-9 DAN VEGF) 
DI KALANGAN WANITA SELEPAS PEMBEDAHAN CAESAREAN 
ABSTRAK 
Channa Striatus (Haruan) digunakan secara meluas di Malaysia untuk 
menggalakkan penyembuhan luka. Sejak turun temurun, C.striatus telah dipercayai 
mempunyai sifat anti-radang, anti-oksida dan anti sakit untuk penyembuhan luka 
yang lebih baik. Penyembuhan luka adalah satu proses dinamik yang melibatkan 
empat fasa yang berbeza namun berlaku secara serentak dan bertindih iaitu 
hemostasis, keradangan, percambahan dan pembentukan semula tisu.  Proses yang 
sangat rumit ini bermula dengan serta-merta selepas kecederaan dan melibatkan 
tindakbalas yang tersusun  antara pelbagai jenis tisu-tisu dan sel-sel. Di dalam proses 
penyembuhan ini, leukosit, makrophaj dan sel endothelial akan mengeluarkan 
pelbagai faktor-faktor pertumbuhan dan sitokin seperti Interleukin 6 (IL-6),  Matrix 
Metalloproteinase-9 (MMP-9) dan Vascular Endothelial Growth Factor (VEGF). IL-
6 mengawal penghasilan leukosit ke kawasan inflammasi.  Fungsi MMP-9 adalah 
mengeluarkan extracellular matrik yang telah rosak, pemindahan sel-sel epidermal 
dan penghasilan semula tisu baru. VEGF pula merangsang pembentukan saluran 
darah baru melalui proses yang dipanggil angiogenesis. Kajian ini dijalankan untuk 
membandingkan paras dan trend IL-6, MMP-9 dan VEGF di dalam kalangan 
pesakit-pesakit mengambil ekstrak C.striatus dan placebo (maltodextrin) dalam 
proses penyembuhan luka untuk wanita yang menjalani pembedahan caesarean 
(LSCS). Kajian ini telah dijalankan secara rawak, double blinded dan kawalan 
plasebo di Hospital USM dan Hospital Raja Perempuan Zainab II. Bagi tempoh 
setiap hari selama 6 minggu, kumpulan yang C.striatus diberikan dos 500 mg serbuk 
xiii 
 
kering ekstrak C.striatus manakala kumpulan plasebo pula diberikan 500 mg 
maltodextrin.  Sampel darah vena diambil dari setiap pesakit selepas pembedahan 
pada hari 1, hari ke-3, minggu ke-2, minggu ke-4 dan minggu ke-6 dan telah 
dianalisa untuk penanda ini. Analisis data dilakukan menggunakan perisian SPSS 
versi 22.  Sejumlah 73 pesakit telah dikaji, 39 pesakit  diberikan ekstrak C.striatus 
dan 34 pesakit lagi diberikan maltodextrin. Daripada kajian ini, didapati bahawa 
perbandingan antara kumpulan ekstrak C.striatus dan kumpulan plasebo 
(maltodextrin) untuk IL-6 dan MMP-9 adalah signifikan pada minggu ke-4 (p < 
0.001, p < 0.05) dan minggu ke-6 (p < 0.001, p < 0.05) masing-masing manakala 
VEGF pula menunjukkan signifikan pada hari 1 (p < 0.05), hari 3 (p < 0.05), minggu 
ke-4 (p < 0.05) dan minggu 6 (p < 0.001). Sebaliknya, perbandingan antara 
kumpulan menunjukkan perbezaan yang tidak signifikan untuk IL-6 dan MMP-9 
pada hari 1 (p = 0.475, p = 0.104), 3 hari (p = 0.131, p = 0.315) dan minggu 2 (p = 
0.052, p = 0.397) masing-masing manakala VEGF pula pada minggu 2 (p = 0.738). 
Kajian ini juga menunjukkan bahawa penanda-penanda ini menunjukkan tren yang 
berkaitan terus dengan proses penyembuhan luka serta membuktikan bahawa 
pengambilan ekstrak C.striatus terlibat dalam membantu meningkatkan proses 
penyembuhan luka. 
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THE EFFECTS OF CHANNA STRIATUS EXTRACT ADMINISTRATION 
ON WOUND HEALING MARKERS ( IL-6, MMP-9 AND VEGF) IN POST 
LOWER SEGMENT CAESAREAN SECTION (LSCS) WOMEN 
ABSTRACT 
Channa striatus (ikan haruan) is widely consumed in Malaysia to promote 
wound healing. For centuries, C.striatus has been proposed to have anti-
inflammatory, anti-oxidant and anti-nociceptive properties for better healing of the 
wound. Wound healing is a dynamic process that involves four disticnt yet an 
overlapping phases; haemostasis, inflammation, proliferation and tissue remodeling. 
It starts immediately after injury and proceeds with a complicated but well-organized 
interaction among various types of tissues and cells. During wound healing process, 
leukocytes, macrophages and endothelial cell release various growth factors and 
cytokines such as interleukin 6 (IL-6), matrix metalloproteinase 9 (MMP-9) and 
vascular endothelial growth factor (VEGF). IL-6 regulates leukocytes recruitment to 
the inflammatory sites. MMP-9 involves in removal of damaged extracellular matrix, 
migration of epidermal cells and tissue remodelling. VEGF  stimulates the new blood 
vessels formation through a process called angiogenesis. This study was done to 
compare the level and trends of IL-6, MMP-9 and VEGF in patients receiving 
C.striatus extract and placebo (maltodextrin) during wound healing of post lower 
segment caesarean section (LSCS). This was a randomized; double blinded, placebo-
controlled study conducted in Hospital USM and Hospital Raja Perempuan Zainab 
II. The treatment group was administered orally with 500 mg of freeze dried 
C.striatus extract daily while the placebo group with 500 mg of maltodextrin daily 
for 6 weeks. Venous blood samples were taken from each subject post-operatively at 
xv 
 
day 1, day 3, week 2, week 4 and week 6 and analysed for healing markers (IL-6, 
MMP-9 VEGF) and safety profile test (FBC, BUSE, Creatinine, ALT and AST). 
Statistical analysis were done using SPSS Version 22. A total of 73 patients were 
studied, 39 patients consumed C.striatus and 34 consumed maltodextrin. From this 
study, the level of wound healing markers ( IL-6, MMP-9 and VEGF) was higher in 
C.striatus extract group compared to placebo. Comparison between C.striatus extract 
group and placebo (maltodextrin) group for IL-6 and MMP-9 were significantly 
different at week 4 (p < 0.001, p < 0.05) and week 6 (p < 0.001, p < 0.05) 
respectively whereas VEGF show significant different at day 1 (p < 0.05), day 3 (p < 
0.05), week 4 ( p < 0.05 ) and week 6 (p < 0.001). In contrast, comparison between 
groups shows no significant different for IL-6 and MMP-9 at day 1 (p = 0.475, p = 
0.104), day 3(p = 0.131, p = 0.315) and week 2 (p = 0.052, p = 0.397) respectively, 
except for VEGF which not significant at week 2 (p = 0.738).This study also shows 
some trends in conjunction with healing phase and shows that the indication of 
C.striatus extract was involved in enhancing the wound healing process.  
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CHAPTER 1 
INTRODUCTION 
 
1.1  Channa striatus 
Channa striatus (Haruan) or snakehead fish, known locally to Malays as 
haruan, is freshwater, air-breather and carnivorous fish indigenous to many tropical 
and subtropical countries including Malaysia which are a valuable source of protein 
throughout the Asia Pacific region (Mat Jais, 2007). For centuries, it has been used as 
traditional medicine for treatment of illness, wound healing supplement and as a 
pharmaceutical among Malaysian populations especially Malays. 
C. striatus has been studied extensively for its commonly believed on wound 
healing properties. It is used by patients in the post-operative period to enhance the 
wound healing processes and to reduce pain (Mat Jais et al., 1997). 
C.striatus is found to contain all the essential amino acid for wound healing 
,particularly glycine which is the most important component of human skin collagen 
(Mat Jais et al., 1998). Several studies have found that, C. striatus also rich in fatty 
acid. Among them, arachidonic acid is most important since it plays an important 
role as a precursor of prostaglandin to initiate blood clotting and be responsible for 
growth. The high reputation of C.striatus  in traditional medicine is due to its 
exceptionally properties such as anti-nociceptive, energy booster, anti-oxidant, anti-
inflammation, wound healing, anti-microbial as well as cardivascular and 
neurological effects (Haniffa et al., 2014).  
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1.2  Wound healing phase 
Wound healing is a dynamic process and involves complex interaction of 
extracellular matrix molecules, solubles mediators and various immune cells (Eming 
et al., 2007). It is best understood as an organism‟s global response to injury, 
regardless of whether the location is skin, liver, or heart (Gurtner, 2007) and well 
described at the histological levels. Classically, wound healing phase involved three 
distinct and overlapping phases : inflammation, new tissue formation (proliferation) 
and tissue remodelling (Schafer and Werner , 2008; Eming et al., 2007). However in 
some literature, wound healing phases are divided into four overlapping processes; 
haemostasis, inflammation, new tissue formation (proliferation) and tissue 
remodelling (DiPietro and Luisa , 1995).  
In the moment where tissue is injured, the normal healing response begins 
with a set of complex biochemical events take place in a closely intergrated cascade 
to repair the damage ( Diegelmann et al., 2004). As the blood components spill into 
the site of injury, the platelets come into contact with exposed collagen and other 
elements of the extracellular matrix , resulting in temporary seal of wound (Eming et 
al., 2007). The activated platelets together with fibrin close off the lymphatic 
channels in the injured area (Myers, 2012). This plug clot also provide provisional 
matrix for cells migration and this initiates the inflammatory phase thus triggers the 
platelets to release various chemotactic agents and chemical mediators, including 
growth factors (such as vascular endothelial growth factor (VEGF), platelet-derived 
growth factors (PDGF) and fibroblast growth factor (FGF) and cell signalling 
chemical known as cytokines (such as interleukin-1(IL-1), interleukin-6 (IL-6) and 
tumor necrosis factor-α (TNF-α) (Gurtner, 2007).  
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In the transition between inflammation and repair, there is a decrease level of 
inflammatory cytokines and immune cells and effect by the release of anti 
inflammatory mediators interleukin-10 (IL-10) and TGF-β1 by macrophages. Other 
cells such as the endothelial cells, fibroblasts and keratinocytes start migrating into 
the wound and proliferate for initiation of second phase of wound healing, the phase 
of new tissue formation. Granulation tissue is the new tissue that initially replaces the 
lost dermis. It consists of fibroblasts, endothelial cells and inflammatory cells 
(Gurtner, 2007). The granulation tissue is continuously replenished by new blood 
vessels in order to support the new tissues with oxygen and nutrients (Schafer and 
Werner, 2008). Termination of wound healing process is by a long remodelling phase 
(Schafer and Werner, 2008) whereby, the fibroblasts differentiate to myofibroblasts, 
which are responsible for formation of collagen and other extracellular matrix protein 
and also for wound contraction (Schafer and Werner , 2008). Among the mediators 
involved in wound healing, interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-
9) and vascular endothelial growth factor (VEGF) is chosen in this study to represent 
different type of markers ; cytokine, enzyme and growth factor respectively. 
 
1.3  Wound healing markers 
Interleukin-6 is a proinflammatory cytokines that has long been thought to 
play an important role in wound repair (Eming et al., 2007). The role of interleukin-6 
(IL-6) is well known as a proinflammatory cytokines which is crucial for kick-
starting of the healing response and was shown to be up regulated in inflammatory 
phase of healing (Ringsdorf and Cheraskin,1982). There are diffrent types of cells 
involve in stimulation of IL-6 secretion such as fibroblast, macrophages, endothelial 
cells and keratinocytes in response to multiple stimuli together with other cytokines 
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such as interleukin-1, tumor necrosis factor and platelet-derived growth factor 
(Grossman et al., 1989).  IL-6 could help initiate the cellular factors in the local 
inflammatory infiltrate such as T cells, macrophages and polymorphonuclear 
neutrophils (PMNs), give rise to an intensification of the local wound (Grossman et 
al., 1989). The coordinated expression of this cytokine is important for normal repair, 
since reduced expression seen after wounding of healing-impaired glucocorticoid-
treated mice (Ringsdorf and Cheraskin,1982, Werner and Grose,2003) and prolonged 
in genetically diabetic mice (Werner and Grose,2003). A study on IL-6 knock-out 
mice, showed that, it took up three times longer for the wound to heal than those of 
wild type control (Galluci et al.,2000;Werner and Grose, 2003). These abnormalities 
were rescued by administration of recombinant murine IL-6 protein one hour before 
wounding. Thus it appears that IL-6 is crucial for kick-starting the healing response 
(Eming et al., 2007). A complete lack of it causes impaired healing and excessive 
level of IL-6 have been associated with cutaneous scarring (Werner and Grose,2003) 
and also in epidermal hyperplasia as shown in psoriasis patients (Grossman et al., 
1989).  
Matrix metalloproteinases (MMP-9) known as gelatinase B are family of 
structurally related, zink-dependent endopeptidases and play an important role in the 
proteolytic remodeling by degrading most of the structural components of 
extracellular matrix (ECM) in various physiologic condition including tissue repair 
(Iba Y et al., 2004). MMP-9 is produced during inflammation phase by inflammatory 
cells including the PMNs, monocytes, macrophages and keratinocytes and their 
concentration levels are gradually decreases after the initial burst and also 
coordinated by hormones, growth factors, and cytokines, and also involved in 
ovarian bioactivity. A sustaintial elevated level of MMP-9 is found in chronic wound 
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cases while low levels are found in excessive scar formation. MMP-9 enzymes are 
secreted as zymogens, which in turn treated by other proteolytic enzymes (such as 
serine proteases, furin, plasmin and others) to provoke the active forms (Verma and 
Hansch, 2007).  
Vascular endothelial growth factor (VEGF) is sub-family of growth factor, 
specifically platelet derived growth factor (PDGF) family of cystine-knot growth 
factors. They are important signaling proteins involved in both vasculogenesis and 
angiogenesis. The important role of VEGF for the healing process is supported in 
several studies where reduced expression of VEGF or its accelerated degradation 
were found to be associated with wound healing defect. Furthermore, treatment of 
wound with VEGF accelerated healing process. Recently one study has shown, 
application of neutralizing antibodies to VEGF caused a striking reduction in wound 
angiogenesis, fluid accumulation and granulation tissue formation in pig model 
(Howdieshell et al., 2001). In another study in human wound fluid, the angiogenic 
activity was strongly inhibited by VEGF neutralization (Werner and Grose , 2003).  
 
1.4  Rationale of study 
Although there are many extensive studies have been done on the effect of C. 
striatus in wound healing, the clinical trial on human is rarely done. The true and 
specific biological effects of this fish in the improvement of wound healing remain 
unclear because of the lack of study in human subjects.  
This study was done to assess the effect of orally administered C.striatus 
extract that may possible have a role in wound healing. This study would observe at 
the selected markers to substantiate the claims. Subjects among post LSCS women 
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were chosen in this study because this group is the commonest group that consumes 
C.striatus to promote wound healing after delivery. 
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CHAPTER 2 
OBJECTIVE AND HYPOTHESIS 
 
2.1 Objective of the research 
2.1.1 The general objective of this study was to evaluate the effects of C.striatus 
extract consumptions on wound healing markers among post Lower 
Segment Caesarean Section (LSCS) women. 
2.1.2 The specific objectives were :  
a. To compare  the level of wound healing markers ( IL-6, MMP-9 and 
VEGF) between C. striatus (ikan haruan) extract group and Placebo 
(maltodextrin) group among post lower segment caesarean section 
(LSCS) women 
b. To observe the trend of the wound healing markers within groups 
(C.striatus group as well as placebo group). 
c. To observe the trend of the wound healing markers between groups 
(C.striatus group and placebo group). 
 
2.2 Benefit of the study 
 Since this fish is widely consumed by the population for the medicinal 
value and with the believe that it fasten the wound healing process, this study 
will provide scientific evidence on the biomedical potential of C.striatus 
(Haruan) as claimed. This study would also promote and commercialise 
C.striatus product and unravelled the biomedical potential of the fish. It is 
also set as research platform to higher value-capture in agricultural sector 
thus generate ideas for further studies regarding the medical use of this fish. 
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These initiatives can help expedite higher value-capture in agricultural sector 
thus generate greater economic activities and lay foundation for a sustainable 
agro-based industry driven by agro-biotechnology development.   
 
2.3 Research hypothesis 
 There are differences in the level and trend of wound healing markers (IL-
6, MMP-9 and VEGF) in post LSCS women who consumed C.striatus extract 
compared to placebo. 
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CHAPTER 3 
LITERATURE REVIEW 
 
3.1 Wound Healing  
 
Wound can be defined as a break in the epithelial integrity which could range 
from simple to severe. Severe deep wound causes multiple destructions throughout 
all tissue structures. It involves cell layers and lineages from both sides (inside and 
outside) including epidermal keratinocyte layer (outmost skin layer), epidermal 
appendages (such as sweat glands and hair follicle), basement membrane (epidermis 
and dermis) which also involves complex cellular structure such as fibroblast, nerves, 
extracellular matrix and blood vessel (Shaw et al., 2009). Depending on the depth of 
the wound, it can even involve other body structures such as nerves, muscles, 
tendons, parenchymal organs and bone as well (Velnar et al., 2009). 
  Wound healing is a dynamic and interactive continual biological activity in 
living cell which start in split second following tissue injury (Zi-Qing Lin et al., 
2003). Its process encompasses of complicated well-organized biological process 
involving many biomarkers, enzymes and cell-signalling events (Diegelmann et al., 
2004) to recover and stabilize the physiology normal function and activity of 
tissue/organ after the physical disruption (Gurtner, 2007). All of the reactions in the 
healing process dependent on energy and nutrition such as micronutrients, protein, 
carbohydrates, fat and amino acids (Arnold and Barbul, 2006). Wound healing 
process is divided into four sequential, distinct and overlapping phase as shown in 
Figure 3.1. The four phases are haemostasis phase, inflammatory phase, proliferation 
phase and tissue remodelling phase. In some literature, only three phases of wound 
healing were elaborated (Gurtner et al., 2008). Haemostasis phase and inflammation 
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phase are considered as one as both occurs concurrently. This phase is called as the 
inflammation phase.  
 
Figure 3.1 Wound healing phases (Adapted from : Brenner K., 2010). 
 Many factors can affect wound healing. It can be divided into local and 
systemic factors as shown in Table 3.1 (Guo and DiPietro, 2010). According to Guo 
and  DiPietro (2010),  local factors are mainly cause by the symptom arise from the 
wound itself, whereas a systemic factors referred to an individual health status that 
could affect the healing mechanism such as chronic diseases. 
Hypertrophic scars or non-healing chronic wounds (ulcers) occur as a result 
of improper wound healing. Chronic wounds are presenting the most prevalent 
wound healing problems in people which also associated with a small number of well 
defined, clinical entities, in particular venous insufficiency, diabetes mellitus, 
pressure necrosis, and vasculitis (Eming et al. 2007). 
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Table 3.1 Factors affected wound healing mechanism (Guo and DiPietro,2010) 
Local factors Systemic factors
Oxygenation Age and gender
Infection Sex hormones
Foreign body Stress
Venous sufficiency Ischemia
Obesity
Alcoholism and smoking
Nutrition
Diseases: diabetes, keloids, fibrosis, 
hereditary healing disorders, jaundice, 
uremia
Medications: glucocorticoid steroids, non-
steroidal anti-inflammatory drugs, 
chemotherapy
Immunocompromised conditions: cancer, 
radiation therapy, AIDS
 
 All the above factors could result in non-healing wounds as it interferes with 
the normal physiological process of wound healing. 
3.1.1 Haemostasis phase 
 In split second after tissue injury, coagulation and haemostasis phase begin 
followed by inflammatory phase. This phase lasts for 24 to 48 hours (Gurtner, 2007) 
and requires the combination activity of vascular, platelet, and plasma factors. 
During this phase, platelets play a critical function by forming an immediate 
supportive web-like matrix so call a fibrin clot or blood clot to prevent blood loss and 
enhance the collagen accumulation at the wound area as shown in Figure 3.2. Initial 
platelet adhesion factor secreted by endothelial cells into the sub endothelium. The 
clot also acts as a transitional matrix to which growth factors bind and set up the 
movement of a cell space (Shaw et al., 2009).  In the meantime, platelets also 
stimulate the next healing phase by producing various cytokines and growth factors 
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which is responsible for promoting various mechanisms such as angiogenesis, 
inflammation and attraction of keratinocytes and fibroblast into the wound area 
(Shaw et al., 2009). Approximately over 300 signalling molecules are segregated 
from activated platelets (Young et al., 2001). Once formation of platelet plugs and 
fibrin clot are stable, next phase of wound healing which is inflammation phase 
begins. Abnormalities in this haemostasis phase can lead to excessive bleeding or 
thrombosis. 
 
Figure 3.2 Haemostasis phase pathway diagram  ( Adapted from : Digplanet : 
Hemostasis, 2009)  
3.1.2 Inflammation phase 
 This phase begins immediately with haemostasis and leads to inflammation. 
Inflammation is a key phase of wound healing that is required to protect against 
infection. There are 4 types of key cells involve directly in inflammatory phase as 
shown in Table 3.2. Platelets that form the clotting or thrombus release several 
growth factors that promote the chemotaxis and proliferation of inflammatory cells 
(Gurtner, 2007). Resident immune cells such as mast cells, T cells and Langerhans 
cells are rapidly activated to release chemokines and cytokines (Shaw et al., 2009). 
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Platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF-β) 
are two types of important cytokine release by platelet (Gurtner, 2007). They are 
important chemo attractant which promote the migration of macrophage, smooth 
muscle, fibroblast and polymorphonuclear neutrophils (PMNs) to the wound. Within 
hours after injury residential mast cells degranulation and become less plausible. 
About 48 hours later, mast cells activity become normal, and rises in number as 
tissue repair progresses (Eming et al., 2007).  
Table 3.2 Type of cells involve in inflammatory phase and its function (Myers, 
2012) 
Cell Functions
Platelet 1. Forming fibrin clot to control and stop the bleeding
2. Secretes growth factor and chemotactic agents (cytokines)
1. First cell arrive to wound area
2. Act as scavenger or hunter 
3. Kill bacteria 
4. Cleans wound area
5. Produce inflammatory mediators and MMPs
Macrophages 1. Manage and promotes healing process
2. Kill bacteria (phagocytosis) and cleaning wound area
3. Produce growth factors and MMPs
Mast cell 1. Release enzyme to destroy damage cells.
2. Secretes inflammatory mediators
Polymorphonuclear 
neutrophils(PMNs)
 
Within one hour, PMNs are among the first inflammatory cells arrived into 
wound area and become predominant cells after 24 hours. PMNs migrate towards the 
wounded area by amoeboid-like movements known as diapedesis (Myers, 2012). 
They work by eliminating all debris and bacteria by mechanism called phagocytosis. 
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They also clear death and damaged tissue by secreting an enzyme called protease that 
breakdown unwanted tissue from wounded area. By this mechanism, wound areas 
are clean and ready for formation of collagen through proliferation phase stimulated 
by fibroblast (Young et al., 2001).  
Within a few days, PMNs activity slows down and is replaced by macrophage 
and lymphocytes. Once all the contaminating bacteria have been eliminated, PMNs 
are eliminated from the wound after completing their task prior to breakthrough to 
the next phase of healing. The cell remnants and apoptotic bodies are then digested 
by macrophages (Velnar et al., 2009). Macrophage is believed to be the predominant 
cells two days after injury and involve in promoting angiogenesis. 
Macrophage is the primary source of pro-inflammatory cytokine (Interleukin-
6), growth factor (such as vascular endothelial growth Ffactor (VEGF)) and 
proteolysis enzymes (matrix metalloproteinase (MMP‟s). Other roles of macrophages 
are killing pathogens by releasing nitrous oxide and bactericidal enzymes (Myers, 
2012). At the end of this phase, formation of extracellular matrix and re-
epithelialization begins together with angiogenesis and formation of tissue 
granulation (Turabelidze et al., 2012). Once the fibrin complexes are cleared by 
fibrinolysis enzymes, the activated keratinocytes migrate along the interface between 
the clot and the underlying healthy dermis to aid the re-epithelialization of new 
epithelial cells (Hoeben et al., 2004). Signs of inflammation at this phase are pain, 
swelling, redness, warmth and decreased function and commonly known in Latin 
words;” tumor, rubor, calor, dolor and functio laesa” (Myers, 2012).  
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3.1.3 Proliferation phase 
 In the proliferation or known as tissue repairing phase, TGF-β stimulates the 
macrophages to secrete fibroblast growth factor (FGF), PDGF, tumour necrosis 
factor alfa (TNF-α) and interleukin ( Diegelmann et al., 2004) to initiate new tissue 
formation. Table 3.3 list four main cells involve in proliferation phase and its specific 
function. There is an extensive growth of epithelial cells under the scab that bridges 
the wound.  
Table 3.3 Main cells involved in proliferation phases and its function (Myers, 
2012) 
Cell Function
Angioblast Forming new blood vessel
Fibroblast Builds granulation tissue and collagen
Myofibroblast Causes wound contraction
Keratinocyte Re-epithelializes wound surface
 
Fibroblast forming a network of collagen in wound bed which gives strength 
to tissue matrix and this process depends on zinc, oxygen and ascorbic acid. The 
proteolytic matrix metalloproteinases (MMPs) facilitate the movement of fibroblast 
within the provisional matrix (Shah et al., 2012). TGF-β stimulates the secretion of 
proteoglycans and fibronectin in the proliferative phase to induce the protein matrix 
formation and promoting a new connective tissue formation to fill in wound 
(Diegelmann et al., 2004). Meanwhile, anti-inflammatory cytokines such as IL-10 
and TGF-β produced by macrophages inhibit and reduce the inflammatory cytokine. 
More oxygen and nutrients are needed to support this high metabolic activity. New 
blood vessels are produced by a process known as angiogenesis or 
neovascularization in order to transport oxygen and nutrients to the wound area at the 
same time removing the end product and toxin from the area (Nieves et al., 2009).  
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Angiogenesis mechanism led by angioblasts is regulated and induced by 
vascular endothelial growth factor (VEGF). VEGF is secreted by epidermal cell, 
fibroblast, macrophage and vascular endothelial cell (Diegelmann et al., 2004). 
Angiogenesis is an example of a process that occurs during wound healing that 
requires adhesion of cells to the ECM in order for them to respond to growth factors. 
Once the angiogenic switch is induced, the formation of new blood vessels, a 
complex and highly regulated sequence of events takes place. Multiple proteases are 
activated and this pathway promotes the degradation of the basement membrane 
surrounding the existing vessel. This is followed by increased proliferation of 
endothelial cells and in turn the formation of a lumen as well as a new basement 
membrane. Finally, the newly formed vessels are fused together. With adequate 
oxygen supply into wound area, the proliferation phase and cellular functions are 
maintained (Youn, 2001).  
Later, some of fibroblast within the healing site are transformed into 
myofibroblast and act as smooth muscles pulling the wound edge together. These 
mechanisms are called wound contraction and are affected by the shape, depth and 
wound size. Wound contraction is an important part of wound healing as it means 
that the body does not have to make as much granulation tissue to fill in the wound 
cavity. The tensile strength of the wound is increased during this stage of the healing 
process and this process continues into the next phase, the maturation and tissue 
remodelling phase. 
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3.1.4  Tissue remodelling phase 
The remodelling phase is triggered when wound has filled in and re-surfaced. 
This phase begins at about 2 to 3 weeks and could last from 21 days to a year 
(Gurtner, 2007). At this time, the production of collagen and tissue degradation have 
reached equilibrium phase. Tissue remodelling and scar formation are mainly 
influenced and promoted by the effects of TGF-β on fibroblasts. TGF-β induces the 
synthesis of collagens and glycosaminoglycans thus stimulate the fibroblast function 
to reorganize and cross-links the collagen. Collagen remodelling is also regulated by 
matrix metalloproteinase (MMP‟s) that are produced by macrophage, fibroblast and 
endothelial cells. There are many types of MMPs, however MMP-9 are involved 
directly in the contraction and remodelling of scar tissue in the extracellular matrix by 
removing and replacing with new and highly organised tissue structure (Gibson et al., 
2009). Fibroblast in contracting wound increases actin microfilaments and the area is 
designated as myofibroblast which then pull collagen fibres together. In turn, this 
normal process closes wound from the external environment with new cell barriers. 
Most myofibroblast diminished themself through programmed suicide process known 
as apoptosis (Shaw et al., 2009). After 3 months, tensile strength of the wound 
gradually increased and reaches about 50% of original tensile strength (Young et al. 
2001). The recovered tensile strength in a wounded area reduced about 20% 
compared to the original tissue strength (Diegelmann et al., 2004). In cases where the 
wound recurs in the same area, the maximum tensile strength will achieve 
approximately 64% out of 80% of original tissue strength (Myers, 2012).  
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3.2 Wound healing markers 
Wound healing markers have been studied extensively. As shown in Table 
3.4, there are examples of some wound healing markers and that have been 
reported and studied nowadays. Many endless and comprehensive studies done 
by researchers around the globe have identified many biochemical pathways and 
molecules that correlate with wound healing activity. Mostly, platelets, 
neutrophils, macrophages and fibroblast commit important role in the wound 
healing process by secretion of various cytokines and growth factors (Shah et al., 
2012).   
Table 3.4 List of some cytokines, growth factors, and enzymes involved in 
the wound healing process (Shah et al., 2012) 
 
 The biological activity of many cytokines and growth factors is mediated by 
activation of a signal transducer and activator of transcription which expose typical 
functional pleiotropic and redundancy characteristic (Scheller et al., 2011). 
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Clinically, some of wound healing markers are useful in diagnosis and treatment of 
several diseases. VEGF for instance, are clinically used as therapeutic agent in 
coronary artery disease, lymphedema, lymphangiogenesis, rheumatoid arthritis, 
atherosclerosis, intimal hyperplasia, diabetic retinopathy, psoriasis and tumour 
angiogenesis (Roy et al., 2006).  
In this study three wound healing markers were selected. Each healing 
markers studied represent the different phases and function in the wound healing 
process. Interleukin-6 (IL-6) represents haemostasis and inflammation phase. Matrix 
metalloproteinase-9 (MMP-9) represents the tissue remodelling phases. Vascular 
endothelial growth factor (VEGF) represents angiogenesis process. These markers 
have also been studied by most researchers regarding their role and management in 
certain diseases especially in wound healing process. 
3.2.1 Interleukin-6 (IL-6) 
IL-6 a cytokine that plays a very important role in nearly all aspect of 
inflammation and innate immunity. Interleukins are types of cytokines that were first 
seen to be expressed by leukocytes. Family of this cytokines include IL-6, IL-11, 
leukaemia inhibitory factor (LIF), oncostatin M (OSM), ciliary inhibitory factor 
(CNTF), cardiotropin-1 (CT-1), cardiotrophin-like related cytokine and stimulating 
neurotrophin-1/B-cell stimulating factor 3 (NNT-1), neuropoietin (NPN), IL-27, and 
IL-31 (Heinrich et al., 2003). Also known as B-cell stimulatory factor 2, IL-6 has 
both pro-inflammatory and anti-inflammatory properties (Jurgen Scheller et al., 
2006). It serves as multifunctional cytokine that regulates cell growth and 
differentiation of various tissues. It is also known particularly for its role in host 
defence due to its wide range of immune and hematopoietic activities and its potent 
ability to induce the acute phase response.  
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IL-6 produces inflammatory effects by inducing the transcription of factors in 
multiple pathways of inflammation. IL-6 is a molecule with multiple forms and 
functions, depends on where it is secreted. IL-6 is secreted by various type of cells 
such as macrophage, keratinocytes, endothelial cells and fibroblast (Zi-Qing Lin et 
al., 2003) and it affects various processes including the immune response, 
reproduction, bone metabolism and aging as illustrated in Figure 3.3.  As a response 
to inflammation and infection, IL-6 regulates leukocytes infiltration and recruitment, 
angiogenesis and collagen accumulation into wound area (Scheller et al., 2011).  
 
Figure 3.3 Biological activities of IL-6 in human body (Adapted from : 
Ramandip Singh et al., 2005)  
A study done by Zi-Qing Lin et al. (2003) on IL-6-deficient mice suggests 
that there would be an interruption on all wound healing phase due to lack of IL-6.  
They also found that IL-6 promotes angiogenesis through induction of VEGF 
production. Over production of IL-6 together with TGF-β1 in some pathological 
cases will cause excessive formation of collagen which will lead into the formation 
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of keloids (Turabelidze et al. 2012). Over production of IL-6 has also been involved 
in the pathology of a number of diseases in conjunction with multiple myeloma, 
rheumatoid arthritis, Castleman's disease, psoriasis, and post-menopausal 
osteoporosis (Simpson et al., 1997). Clinically, IL-6 is also used as immune response 
stimulator in chemotherapy for cancer patients (Thomas, 2015). 
3.2.2  Matrix metalloproteinase-9 (MMP-9) 
Matrix metalloproteinases (MMP‟s) also called matrixins (Nagase and 
Woessner , 1999) are referred to a large family of endopeptidases or protease enzyme 
that consist of 25 members out of which 24 of them are found in mammals. They 
utilize Zn
2+
 or Ca
2+
 ion in their active site (Gill and Parks,2008), which are 
responsible for the regulation of  tissue remodelling and degradation of the 
extracellular matrix (ECM), in conjunction with collagens, elastins, gelatines, matrix 
glycoproteins and proteoglycan (Verma et al., 2007) . Inflammatory cells are well 
known to produce MMP‟s. Epithelial and stromal cells in wounded tissue have also 
been demonstrated to secrete multiple MMP‟s (Gill and Parks, 2008)  
 There are many types of MMP‟s that have been associated with wound 
repair, and these include MMP-1, 3, 7, 9, 10, 14, and 28. They are divided into 
collagenases, gelatinases, stromelysins, and matrilysins depends on the physical 
foundation of their specificity (Verma et al., 2007).  
MMP‟s trigger the proliferation and migration of endothelial cells by 
increasing the biological opportunity of pro-angiogenic factors such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2) and 
transforming growth factor β (TGF-β) but reversely produce fragments that are 
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angiogenesis inhibitors. MMP‟s therefore represent as both inducers and inhibitors of 
angiogenesis (Di Carlo, 2012). 
MMP-9 also known as gelatinase-B or type IV collagenase, is one of 23 
human MMP‟s that have been widely and extensively studied by researchers 
exclusively related to wound healing processes (Gibson et al., 2009). Since 
angiogenesis involves migration/invasion of endothelial cells into surrounding 
tissues, the degradation of ECM by these proteolytic enzymes would allow the 
invasion of endothelial cells into wound area. However, the complete regulations of 
MMP-9 in angiogenesis pathway are still unclear (Di Carlo, 2012).  
Among all cell types, macrophages secreted more MMP-9 compared to 
neutrophils, lymphocytes and stromal cells. MMP-9 are neutral proteinases that are 
involved in the breakdown and remodelling of the extracellular matrix (ECM) under 
a variety of physiological and pathological conditions, such as morphogenesis, 
differentiation, angiogenesis, as well as pathological processes including 
inflammation, arthritis, cardiovascular diseases, pulmonary diseases and tumour 
invasion (Gam et al., 2006). They degrade ECM with subsequent activation of major 
pro-angiogenic factors such as vascular endothelial growth factor and fibroblast 
growth factor. The level of MMP-9 is regulated by endogenous inhibitors so called 
tissue inhibitors of metalloproteinase (TIMPs). In addition, there are other substances 
and mechanisms that inhibit metalloproteinase activity such as α2-macroglobulin, a 
primary inhibitor of metalloproteinases in bodily fluid.  
Modification reactions by reactive oxygen species also have been exhibited to 
cease the bioactivity of MMP-9 (Gill and Parks, 2008). High levels of MMP-9 causes 
23 
 
improper deposition of protein matrix on wound area (Shah et al., 2012) and tissue 
damage if untreated with anti-oxidant (Gibson et al., 2009). 
3.2.3 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor was found in 1983 is a secretory protein 
which consist of  seven family member, VEGF-A, B, C, D, E, F and placental growth 
factor (PIGF). It has the capability to aid an expansion of vascular permeability in 
endothelium cells (Nieves et al., 2009) and serve as main stimulator of angiogenesis 
(Di Carlo,2012). VEGF has been identified as one of the most potent and 
predominant among the many factors implicated in angiogenesis. There are many 
publications about VEGF that have been published involving diagnostic and 
therapeutic drug monitoring (Jelkman,2001). VEGF can induce growth of pre-
existing (angiogenesis) or de novo vessels (vasculogenesis). This action of VEGF 
ensures that it is critical within embryonic development as well as vessel repair 
during wound healing process. VEGF plays an important role in both normal and 
pathological angiogenesis and being used as an indicator in cardiovascular disease, 
malignancies and inflammatory disease (Jelkman,2001). VEGF also serve as an 
endothelial cell mitogen and chemotactic or chemo attractant agent (Bao et al., 
2009). Recently, numerous studies have also emphasized the role of VEGF in 
pathological conditions involving the formation of new blood vessels, cancer, 
rheumatoid arthritis and age-related macular degeneration. An increased serum 
VEGF levels is useful for the prognosis of increased tumour growth, recurrence, or 
metastatic spread in individual patients (Hoeben et al., 2004). Majority of the studies 
showed circulating serum VEGF had positive correlation with tumour stage or 
patient survival, by that supporting the clinical relevance of VEGF in cancer patients 
(Hoeben et al., 2004). 
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 All VEGF members have common homology territory and are encoded by 
multiple exons that can give rise to different isoforms after alternative slicing. The 
gene expressions of VEGF are stimulated by several pro-inflammatory cytokines 
such as IL-6 and TNF-α (Jelkman, 2001). Specifically, VEGF-A is characterized by 
seven isoforms with 121, 145, 148, 165, 183, 189, or 206 amino acids, while VEGF-
B presents two isoforms, with 167 and 186 amino acids. Although these isoforms 
behave identically in solution, they differ in their ability to bind heparin and the 
extracellular matrix.  Amongst the family members, VEGF-A is the most dominant 
inducer of blood vessel growth known to date. VEGF-A is a dimeric, disulphide-
bound glycoprotein and exists in at least seven homodimeric isoforms. Normally the 
highest levels of VEGF- A mRNA are found in adult lung, kidney, heart, and adrenal 
gland (Hoeben et al. 2004). By binding to VEGFR-2 receptor, VEGF increased cell 
permeability and also activate the production of guanylyl cyclase, cGMP through the 
present of nitric oxide (Roy et al., 2006). VEGF-A also involve in enhancing the 
transportation of oxygen and nutrition into wounded area (Hoeben et al., 2004). 
 VEGF-B was discovered since 1995 and abundantly found in the adult 
myocardium, skeletal muscle and pancreas. Role of VEGF-B remains unclear even 
though several studies have been done (Scheller et al., 2011). Roy et al. found that 
VEGF-B plays an important role in inflammatory angiogenesis (Roy et al., 2006) 
with 88% amino acid sequence homology to VEGF-A. 
VEGF-C is produced mostly in heart, placenta, ovary, small intestine and the 
thyroid gland, whereas in embryonic tissue, the production occurs where lymphatic 
vessels undergo sprouting from embryonic veins, such as the perimetanephric, 
axillary and jugular areas (Hoeben et al., 2004). The main role of VEGF-C is as 
lymphangiogenic growth factor and regulated by VEGFR-3 receptor (Scheller et al., 
